Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

EHR Alerts to Improve GLP-1 Medication and Continuous Glucose Monitor Prescribing in Primary Care

17 november 2026 uppdaterad av: Montefiore Medical Center

Evaluation of Quality Improvement Initiative to Improve GLP-1 and CGM Prescription Rates

This randomized quality improvement study will evaluate whether pop-up alerts in the electronic health record (EHR) increase prescribing of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications and continuous glucose monitors (CGMs) for eligible patients with diabetes. The study will be conducted at nine Montefiore Medical Group primary care sites. Primary care providers will be randomly assigned to either receive the alerts or not receive them. The alerts will remind providers that a patient is eligible for a GLP-1 RA, a CGM, or both, and will help them choose the option covered by the patient's insurance. Providers in both groups will use their own clinical judgment in deciding whether to prescribe. The study will use information already recorded in patients' medical records.

Studieöversikt

Status

Rekrytering

Detaljerad beskrivning

Primary care providers (physicians, physician assistants and nurse practitioners) are randomized 1:1, stratified by site type (teaching vs. non-teaching), prior GLP-1 RA prescribing, and eligible-patient volume. Approximately 121 providers will be randomized. The patients they see who meet eligibility criteria during the study period are the enrolled participants and are reflected in the enrollment count. Residents and their patients are excluded. For providers in the intervention arm, the alert is an Our Practice Advisory (OPA) in Epic that fires during qualifying in-person or telehealth primary care visits. Patients eligible for both a GLP-1 RA and a CGM trigger a single combined alert; patients eligible for only one trigger only that portion of the alert. Intervention-arm providers also receive education on using the alert. Outcomes are analyzed at the patient level using only each patient's first qualifying visit. The analysis uses mixed-effects logistic regression with a random effect for provider.

Note: The Albert Einstein College of Medicine Institutional Review Board (IRB) determined this quality improvement project does not meet the definition of human subjects research. An IRB determination letter is on file with this registration.

Studietyp

Interventionell

Inskrivning (Beräknad)

2989

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • New York
      • The Bronx, New York, Förenta staterna, 10467
        • Rekrytering
        • Montefiore Medical Center
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 85 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Meet Klompas definition of diabetes
  • Has at least one primary care visit, in-person or telehealth, during the study period
  • Is covered by Medicare or Medicaid

Additional inclusion criteria for the GLP-1 portion of the OPA alert:

  • GLP-1 component: HbA1c ≥ 9 on most recent lab test in the past 12 months and a BMI ≥ 25) OR BMI ≥ 30, and no GLP-1 prescription in the past 12 months

Additional inclusion criteria for the CGM portion of the OPA alert:

  • CGM component: Insulin prescription in the past 12 months and no CGM prescription in the past 12 months

Exclusion Criteria:

  • Patients seen by residents during their first visit

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Hälsovårdsforskning
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Our Practice Advisory (OPA) Alert

Education will be provided on the use of the alerts to PCPs in the intervention group. Providers will continue using clinical judgment for the appropriateness of the GLP-1 medication or CGM device for their patients.

Electronic Health Record (EHR) Our Practice Advisory, a pop-up electronic notification for clinical staff available at the time of a clinical encounter in the electronic medical record, recommending the insurance-preferred GLP-1 and/or a CGM, plus education for providers on using the alerts

Inget ingripande: Usual Care (UC)

Providers continue usual care, with no alert. Providers will use clinical judgment for the appropriateness of the GLP-1 medication or CGM device for their patients.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of Eligible Patients Newly Prescribed an Insurance-preferred GLP-1 medication
Tidsram: At the first qualifying primary care visit during the study period, up to 3 months

The percentage of patients meeting the GLP-1 RA alert eligibility criteria who are newly prescribed a GLP-1 RA covered by their insurance, as documented in the electronic health record. GLP-1 RAs not covered by the patient's insurance are not counted. Each patient's first qualifying visit during the study period is analyzed.

At the first qualifying primary care visit during the study period, up to 3 months
Percentage of Eligible Patients Newly Prescribed a CGM
Tidsram: At the first qualifying primary care visit during the study period, up to 3 months

The percentage of patients meeting the CGM alert eligibility criteria who are newly prescribed a continuous glucose monitor (CGM), as documented in the electronic health record. Each patient's first qualifying visit during the study period is analyzed.

At the first qualifying primary care visit during the study period, up to 3 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Provider Response to the OPA alert
Tidsram: Throughout the study period, up to 3 months

For the OPA arm only, providers interaction with the OPA alert will be evaluated based on the percentage of time the OPA alert fired and was either: ignored, declined, and approved. The unit of analysis are patients. Each nominal categorical variable will be summarized.

Throughout the study period, up to 3 months
Reasons for Declining the OPA alert
Tidsram: Throughout the study period, up to 3 months

Among alert firings declined by providers in the OPA Alert arm, the percentage for each decline reason selected in the electronic health record will be summarized. The reasons are: Defer to Next Visit; Patient Declines; Chart Review Only; Does Not Meet Criteria; Financial Limitations; Treatment Ineffective; Patient Can't Tolerate. The unit of analysis are patients.

Throughout the study period, up to 3 months
Percentage of Eligible Patients Newly Prescribed an Insurance-preferred GLP-1 medication by Patient Characteristics
Tidsram: Throughout the study period, up to 3 months

Primary outcome evaluated by patient Body Mass Index (BMI) category, HbA1c category, Insulin status, Age group, Sex, and Race/Ethnicity. The unit of analysis are patients.

Throughout the study period, up to 3 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Shivani Agarwal, MD, MPH, Montefiore Medical Center

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 november 2026

Primärt slutförande (Beräknad)

1 mars 2027

Avslutad studie (Beräknad)

1 mars 2027

Studieregistreringsdatum

Först inskickad

5 november 2026

Först inskickad som uppfyllde QC-kriterierna

17 november 2026

Första postat (Faktisk)

19 november 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera